Kymera Therapeutics (NasdaqGM:KYMR) Q4 2025 Earnings call February 26, 2026 08:30 AM ET Company ParticipantsAnna Lee - VP in Equity ResearchBrad Canino - Managing DirectorBruce Jacobs - CFOCharles Ndiaye - Biotech Equity Research AssociateEdward Tenthoff - Managing DirectorFaisal Rashid - Managing DirectorGeoff Meacham - Managing DirectorJared Gollob - Chief Medical OfficerJustine Koenigsberg - VP of Investor RelationsKevin Cullinane - Managing DirectorMarc Frahm - Managing DirectorNello Mainolfi - Founder, ...

argenx (NasdaqGS:ARGX) Q4 2025 Earnings call February 26, 2026 08:30 AM ET Company ParticipantsAkash Tewari - Global Head of Biopharmaceutical ResearchAlex Thompson - Managing DirectorBeth DelGiacco - VP of Corporate AffairsDanielle Brill - Managing DirectorDouglas Tsao - Managing DirectorJames Gordon - Director and Head of European PharmaJustin Smith - DirectorKaren Massey - COOKarl Gubitz - CFOLuc Truyen - Chief Medical OfficerMatt Phipps - Partner and Group Head of BiotechnologyRajan Sharma - Executive D ...

Kymera Therapeutics (NasdaqGM:KYMR) Q4 2025 Earnings call February 26, 2026 08:30 AM ET Company ParticipantsAnna Lee - VP in Equity ResearchBrad Canino - Managing DirectorBrian Abrahams - Head of Global Healthcare ResearchBruce Jacobs - CFOCharles Ndiaye - Biotech Equity Research AssociateEdward Tenthoff - Managing DirectorFaisal Rashid - Managing DirectorGeoff Meacham - Managing DirectorJared Gollob - Chief Medical OfficerJustine Koenigsberg - VP of Investor RelationsMarc Frahm - Managing DirectorNello Mai ...

Catalyst Pharmaceuticals (NasdaqCM:CPRX) Q4 2025 Earnings call February 26, 2026 08:30 AM ET Company ParticipantsJeff Del Carmen - EVP and Chief Commercial OfficerMike Kalb - EVP and CFORich Daly - President and CEONone - Company RepresentativeConference Call ParticipantsJason Dorr - Research AnalystKeith Savon - AnalystLuke Herrmann - Research AnalystPavan Patel - Biopharma Equity Research AnalystNone - AnalystNone - AnalystOperatorGood morning, thank you for standing by. My name is John, and I will be you ...

Kymera Therapeutics (NasdaqGM:KYMR) Q4 2025 Earnings call February 26, 2026 08:30 AM ET Speaker15Good day, everyone. My name is Kahealani. I will be your conference operator today. At this time, I'd like to welcome you to the Kymera Therapeutics fourth quarter 2025 results call. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question and answer session. If you'd like to ask a question during this time, and if you've joined via the webinar, pl ...

Ligand Pharmaceuticals (NasdaqGM:LGND) Q4 2025 Earnings call February 26, 2026 08:30 AM ET Speaker7Thank you for standing by, and welcome to Ligand's fourth quarter 2025 earnings call. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question and answer session. If you would like to ask a question during this time, simply press star followed by 1 on your telephone keypad. If you would like to withdraw your question, please press star one again. ...

WOBURN, Mass., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization and development of photodynamic therapy (“PDT”), today announced that on February 23, 2026, the U.S. Patent Trial and Appeal Board (the “Board”) issued a Final Written Decision finding all challenged claims of Sun Pharmaceutical Industries, Inc.’s U.S. Patent No. 11,697,028 (the “’028 Patent”) to be unpatentable. As previously disclosed in Biofrontera’s filings ...

Outpatient treatment enabled under FT819-102 autoimmune basket protocol with patients now treated with FT819 off-the-shelf CAR T-cell therapy as same-day hospital discharge Four systemic sclerosis patients and the first idiopathic inflammatory myopathy patient treated with FT819; First systemic sclerosis patient reaching 3-month evaluation timepoint shows meaningful disease improvement using less-intensive conditioning chemotherapy FT819 Phase 1 enrollment expanded across 16 clinical sites in the U.S., U.K. ...

Core Insights - Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) is recognized as one of the best investment stocks for 2026, indicating strong future potential in the market [1][2]. Company Developments - Truist Securities downgraded HRMY from Buy to Hold due to concerns raised during a patent trial against AET Pharma, suggesting a potential negative outcome for Harmony's case and highlighting risks for the Wakix franchise, with generic competition expected before 2029 [3][8]. - On February 17, the U.S. FDA approved Harmony's supplemental New Drug Application for WAKIX (pitolisant) tablets, allowing treatment for cataplexy in children aged six and older, marking it as the first FDA-approved non-scheduled therapy for narcolepsy [4][5]. Industry Context - Harmony Biosciences focuses on developing therapies for rare neurological disorders, particularly innovative treatments for narcolepsy and other sleep-related diseases, positioning itself within a niche but critical segment of the biopharmaceutical industry [5].

Wedbush lowered the firm’s price target on Apellis (APLS) to $18 from $20 and keeps a Neutral rating on the shares. Overall, the Q4 report from Apellis was largely as anticipated with the company preannouncing key results in January, the firm notes. Management anticipates flat Syfovre pricing into FY26 and more limited growth. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See the top stocks recommended by analysts >> Read More on APLS: Dis ...